Amgen Inc. highlighted its biosimilar portfolio and revealed plans to develop and launch copies of AbbVie Inc.’s Humira (adalimumab) and Johnson & Johnson’s Remicade (infliximab) during an investor meeting in New York City Feb 7.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?